Evidence from four RCTs suggests that bifeprunox may be effective in preventing global state deterioration and reducing positive and negative symptoms in adults with schizophrenia. However, evidence is of low to very low certainty, so no strong conclusions can be drawn.
Compared with cognition‐focused diabetes care for adults with type 2 diabetes mellitus, emotion‐cognition‐focused diabetes care had no clear impact on overall diabetes‐related distress, self‐efficacy, health‐related quality of life, HbA1c level, systolic or diastolic blood pressure, or adverse events.